disability; chest pain; a little thick bladder wall; After vaccination on 20FEB2023 his health went down to Since 20FEB2023 he has been having sharp pain on his pudendal lower left nerves/I just have been pain all the time; This spontaneous case was reported by a consumer and describes the occurrence of DISABILITY (disability) in a 40-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. ASKU) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included COVID-19 (had COVID Disease twice/the second time he had COVID Disease was NOV2021). Concomitant products included HYDROMORPHONE HYDROCHLORIDE (DILAUDID), GABAPENTIN and LORAZEPAM (ATIVAN) for an unknown indication.    On 20-Feb-2023, the patient received third dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 20-Feb-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced NEURALGIA (Since 20FEB2023 he has been having sharp pain on his pudendal lower left nerves/I just have been pain all the time). On an unknown date, the patient experienced DISABILITY (disability) (seriousness criteria disability and medically significant), CHEST PAIN (chest pain), BLADDER HYPERTROPHY (a little thick bladder wall) and IMMUNISATION REACTION (After vaccination on 20FEB2023 his health went down to H....). At the time of the report, DISABILITY (disability), NEURALGIA (Since 20FEB2023 he has been having sharp pain on his pudendal lower left nerves/I just have been pain all the time), CHEST PAIN (chest pain) and BLADDER HYPERTROPHY (a little thick bladder wall) had not resolved and IMMUNISATION REACTION (After vaccination on 20FEB2023 his health went down to H..) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Computerised tomogram: CT scan of abdomen and pelvic area was normal except a little thick bladder wall. On an unknown date, Electrocardiogram: His EKG shows that his heart is healthier.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   Patient received 3 Moderna COVID-19 vaccine so far. The last dose was administered on 20FEB2023. Prior to this vaccine he was totally healthy and never went to a doctor. He does not have his vaccination card available.   Spikevax was reported as suspect and was administered in two shotsShot #1: First Primary monovalent dose  on (Lot# & Exp. Date: unknown). Shot #2: 2nd Primary monovalent dose on (Lot# & Exp. Date: unknown) and the indication for the suspect was COVID-19 Prophylaxis   Patient states that he still can not smell poop right does not remember the date first time COVID. Treatment information was not reported.  Company Comment This spontaneous case concerns a 40-years-old-male patient, with  medical history of COVID-19 disease on two opportunities (the second one on NOV2021); concomitant products included HYDROMORPHONE, GABAPENTIN and LORAZEPAM who experienced the  unexpected seriousness criterion disability and medically significant event of  disability; the unexpected events of neuralgia, chest pain, bladder hypertrophy and immunisation reaction in the context of 3rd.  dose of  mRNA- 1273 bivalent vaccine. Neuralgia event began the same day of the injection; the other events occurred on unknown dates. The current condition of Covid-19 is a contributor for the events. The benefit-risk relationship of mRNA-1273 bivalent vaccine is not affected by this report. Events seriousness was assessed based on medical judgement.